Acknowledgment The development of the Canadian guidelines on osteonecrosis of the jaw was funded by the Canadian Association of Oral and Maxillofacial Surgeons’ Foundation for Continuing Education and Research. The Canadian Task Force on Osteonecrosis of the Jaw comprises the following members: Aliya A. Khan, George K.B. Sandor, Edward Dore, Archibald D. Morrison, Mazen Alsahli, Faizan Amin, Edmund Peters, David A. Hanley, Sultan R. Chaudry, David W. Dempster, Francis H. Glorieux, Alan J. Neville, Reena M. Talwar, Cameron M. Clokie, Majd Al Mardini, Terri Paul, Sundeep Khosla, Robert G. Josse, Susan Sutherland, David K. Lam, Robert P. Carmichael, Nick Blanas, David Kendler, Steven Petak, Louis Georges Ste-Marie, Jacques Brown, A. Wayne Evans, Lorena Rios, Brian Lentle, and Juliet E. Compston. The consensus practice guidelines have been endorsed by the following national and international societies: the Canadian Association of Oral and Maxillofacial Surgeons, the Canadian Society of Endocrinology and Metabolism, the Ontario Society of Oral and Maxillofacial Surgeons, the Canadian Academy of Oral and Maxillofacial Pathology and Oral Medicine, the American Association of Clinical Endocrinologists, the International Bone and Mineral Society, and the International Society of Clinical Densitometry. |
References 1. Marx, RE. Pamidronate (Aredia) and zoledronate (Zometa) induced avascular necrosis of the jaws: a growing epidemic. J Oral Maxillofac Surg. 2003;61(9):1115–7. [PubMed]2. Favus, MJ. Diabetes and the risk of osteonecrosis of the jaw [editorial]. J Clin Endocrinol Metab. 2007;92(3):817–8. [PubMed]3. Khan, AA; Sándor, GKB; Dore, E; Morrison, AD; Alsahli, M; Amin, F, et al. Canadian consensus practice guidelines for bisphosphonate associated osteonecrosis of the jaw. J Rheumatol. 2008. Jun 1. [Accessed 2008 May 30]. Epub ahead of print. Available from: http://jrheum.com/earlyrelease.html. 4. Advisory Task Force on Bisphosphonate-Related Osteonecrosis of the Jaws, American Association of Oral and Maxillofacial Surgeons. American Association of Oral and Maxillofacial Surgeons position paper on bisphosphonate-related osteonecrosis of the jaws. J Oral Maxillofac Surg. 2007;65(3):369–76. [PubMed]5. Ruggiero, SL; Mehrotra, B; Rosenberg, TJ; Engroff, SL. Osteonecrosis of the jaws associated with the use of bisphosphonates: a review of 63 cases. J Oral Maxillofac Surg. 2004;62(5):527–34. [PubMed]6. Kademani, D; Koka, S; Lacy, MQ; Rajkumar, SV. Primary surgical therapy for osteonecrosis of the jaw secondary to bisphosphonate therapy. Mayo Clin Proc. 2006;81(8):1100–3. [PubMed]7. Lyles, KW; Colón-Emeric, CS; Magaziner, JS; Adachi, JD; Pieper, CF; Mautalen, C, et al. Zoledronic acid in reducing clinical fracture and mortality after hip fracture. N Eng J Med. 2007;1(11) nihpa40967. 8. Brown, JP; Josse, RG. Scientific Advisory Council of the Osteoporosis Society of Canada: 2002 clinical practice guidelines for the diagnosis and management of osteoporosis in Canada. CMAJ. 2002;167(10 Suppl):S1–34. [PubMed]9. Berenson, JR; Hillner, BE; Kyle, RA; Anderson, K; Lipton, A; Yee, GC, et al. American Society of Clinical Oncology clinical practice guidelines: the role of bisphosphonates in multiple myeloma. J Clin Oncol. 2002;20(17):3719–36. [PubMed]10. Berry, S; Waldron, T; Winquist, E; Lukka, H. The use of bisphosphonates in men with hormone-refractory prostate cancer Practice guideline report No. 3–14. Toronto, ON: Cancer Care Ontario; 2005. [Accessed 2008 May 30]. Available from: www.cancercare.on.ca/pdf/pebc3-14s.pdf. 11. Berry, S; Waldron, T; Winquist, E; Lukka, H. The use of bisphosphonates in men with hormone-refractory prostate cancer: a systematic review of randomized trials. Can J Urol. 2006;13(4):3180–8. [PubMed]12. Hillner, BE; Ingle, JN; Chlebowski, R; Gralow, J; Yee, JC; Janjan, NA, et al. American Society of Clinical Oncology 2003 update on the role of bisphosphonates and bone health issues in women with breast cancer. J Clin Oncol. 2003;21(21):4042–57. [PubMed]13. Kyle, RA; Yee, GC; Somerfield, MR; Flynn, PJ; Halabi, S; Jagannath, S, et al. American Society of Clinical Oncology 2007 clinical practice guideline update on the role of bisphosphonates in multiple myeloma. J Clin Oncol. 2007;25(17):2464–72. [PubMed]14. Saad, F; Gleason, DM; Murray, R; Tchekmedyian, S; Venner, P; Lacombe, L, et al. A randomized, placebo-controlled trial of zoledronic acid in patients with hormone-refractory metastatic prostate carcinoma. J Natl Cancer Inst. 2002;94(19):1458–68. [PubMed]15. Khosla, S; Burr, D; Cauley, J; Dempster, DW; Ebeling, PR; Felsenberg, D, et al. Bisphosphonate-associated osteonecrosis of the jaw: report of a task force of the American Society for Bone and Mineral Research. J Bone Miner Res. 2007;22(10):1479–91. [PubMed]16. Peters, E; Lovas, GL; Wysocki, GP. Lingual mandibular sequestration and ulceration. Oral Surg Oral Med Oral Pathol. 1993;75(6):739–43. [PubMed]17. Bamias, A; Kastritis, E; Bamia, C; Moulopoulos, LA; Melakopoulos, I; Bozas, G, et al. Osteonecrosis of the jaw in cancer after treatment with bisphosphonates: incidence and risk factors. J Clin Oncol. 2005;23(34):8580–7. [PubMed]18. Marx, RE; Sawatari, Y; Fortin, M; Broumand, V. Bisphosphonate-induced exposed bone (osteonecrosis/osteopetrosis) of the jaws: risk factors, recognition, prevention, and treatment. J Oral Maxillofac Surg. 2005;63(11):1567–75. [PubMed]19. Mavrokokki, T; Cheng, A; Stein, B; Goss, A. Nature and frequency of bisphosphonate-associated osteonecrosis of the jaws in Australia. J Oral Maxillofac Surg. 2007;65(3):415–23. [PubMed]20. Dimitrakopoulos, I; Magopoulos, C; Karakasis, D. Bisphosphonate-induced avascular osteonecrosis of the jaws: a clinical report of 11 cases. Int J Oral Maxillofac Surg. 2006;35(7):588–93. [PubMed]21. Cafro, AM; Barbarano, LA; Andriani, A. Osteonecrosis of the jaw associated with chronic bisphosphonates therapy: an Italian experience [abstract]. Blood. 2005;106(11):5152a. 22. Dimopoulos, MA; Kastritis, E; Anagnostopoulos, A; Melakopoulos, I; Gika, D; Moulopoulos, LA, et al. Osteonecrosis of the jaw in patients with multiple myeloma treated with bisphosphonates: evidence of increased risk after treatment with zoledronic acid. Haematologica. 2006;91(7):968–71. [PubMed]23. Durie, BG; Katz, M; Crowley, J. Osteonecrosis of the jaws and bisphosphonates. N Engl J Med. 2005;353(1):99–102. [PubMed]24. Tosi, P; Zamagni, E; Cangini, D; Tacchetti, P; Offidani, M; Ronconi, S, et al. Bisphosphonates and osteonecrosis of the jaws: incidence in a homogeneous series of patients with newly diagnosed multiple myeloma treated with zoledronic acid [abstract]. Blood. 2005;106(11):3461a. 25. Felsenberg, D; Hoffmeister, B; Amiling, M. Bisphosphonattherapie assoziierte. Kiefernekrosen Deutsches Arzteblatt. In press. 26. Lam, DK; Sándor, GK; Holmes, HI; Evans, AW; Clokie, CM. A review of bisphosphonate-associated osteonecrosis of the jaws and its management. J Can Dent Assoc. 2007;73(5):417–22. [PubMed]27. Kyle, RA; Yee, GC; Somerfield, MR; Flynn, PJ; Halabi, S; Jagannath, S, et al. American Society of Clinical Oncology 2007 clinical practice guideline update on the role of bisphosphonates in multiple myeloma. J Clin Oncol. 2007;25(17):2464–72. [PubMed]28. Zavras, AI; Zhu, S. Bisphosphonates are associated with increased risk for jaw surgery in medical claims data: is it osteonecrosis? J Oral Maxillofac Surg. 2006;64(6):917–23. [PubMed]29. Melo, M; Obeid, G. Osteonecrosis of the jaws in patients with a history of receiving bisphosphonate therapy. Strategies for prevention and early recognition. J Am Dent Assoc. 2005;136(12):1675–81. [PubMed]30. Ruggiero, S; Gralow, J; Marx, RE; Hoff, AO; Schubert, MM; Huryn, JM, et al. Practical guidelines for the prevention, diagnosis, and treatment of osteonecrosis of the jaw in patients with cancer. J Oncol Pract. 2006;2(1):7–14. 31. Farah, CS; Savage, NW. Oral ulceration with bone sequestration. Aust Dent J. 2003;48(1):61–4. [PubMed] |